This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves. The study will take in healthy adult participants aged 18 to 65 years who are not able to have children. Eligible participants must weigh more than 50 kilograms (110 pounds) and have a Body Mass Index (BMI) between 18.5 and 27.9. Each participant will receive two treatments: * One treatment with PF-08049820 alone * One treatment with PF-08049820 taken together with rabeprazole Both medicines will be taken by mouth. Participants will stay at the study clinic for a few days during each treatment period. During these stays, the study team will collect blood samples to see how the body absorbs and processes the medicine.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
18
Oral tablets
Oral tablets
Beijing Friendship Hospital Affiliate of Capital University
Beijing, Beijing Municipality, China
Beijing Friendship Hospital Affiliate of Capital University
Beijing, Beijing Municipality, China
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.
Time frame: Day 1 through Day 38-45
PK: Area under the plasma concentration (AUC) of PF-08049820
Time frame: Day 1 through Day 38-45
Number of participants with treatment emergent adverse events
Time frame: First dose through Day 38-45
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.